Form 4: Rallybio Corp Director Helen M Boudreau Acquires Options

Director Helen M Boudreau acquired options to purchase 16,500 shares of Rallybio Corp common stock on May 15, 2024.

Summary

• On May 15, 2024, Helen M Boudreau, a director of Rallybio Corp, was granted options to purchase 16,500 shares of the company's common stock.
• The options were granted under the company's 2021 Equity Incentive Plan with an exercise price of $1.91.
• The options vest on the earlier of May 15, 2025, or the date of the company's 2025 Annual Meeting of Stockholders and expire on May 15, 2034.
• Following the transaction, Boudreau directly owns options for 16,500 shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The grant of options to a director aligns their interests with those of the shareholders.

Industry Context

This is a standard Form 4 filing related to insider transactions, specifically the granting of stock options to a company director. Such grants are common in the biotech industry as a way to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedule of one year is fairly standard.
• The exercise price is $1.91.

Stakeholder Impact

• The granting of options to a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates